Shares of Hims & Hers Health (HIMS) fell sharply in premarket trading on Tuesday after the telehealth company reported weaker-than-expected first-quarter revenue and a surprise loss. The stock dropped ...
・HIMS, however, raised full-year 2026 revenue guidance to $3.1 billion–$3.3 billion and updated adjusted core profit guidance to $275 million–$325 million. ・If the FDA allows compounding, Hims is ...
Hims & Hers Health shares rallied to ~$27 after the early-March Novo deal before resetting to ~$20, still leaving the stock ~40% above prior coverage levels. Short interest remains elevated at ~83.3M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results